Haithem Laaribi

Haithem Laaribi is an Associate at TCGX in New York, where he is involved in equity research and investment analysis with a primary focus on the biotechnology sector, particularly SMID cap (small- and mid-cap) biotech companies. In his current role, he contributes to evaluating public and private biotech opportunities, supporting the firm's crossover investment strategies targeting growth-stage therapeutics and life sciences companies.

Previously, Haithem was a Senior Associate in Biotech Equity Research at Evercore ISI, where he specialized in SMID cap biotech coverage, and before that a consultant at Eversana Consulting and Deallus, gaining broad exposure to healthcare strategy and commercialization. His career has centered on life sciences investing, with an emphasis on therapeutic and biotechnology companies.

Haithem holds a B.Sc. in Pharmacology from McGill University, providing him with a strong scientific foundation for investment analysis in the biotech space. His expertise bridges scientific research and financial markets, making him a valuable contributor to sector-focused investment teams deploying capital in innovative healthcare and therapeutics assets.